Peptomyc Company
Peptomyc focuses on the development of a new generation of cell-penetrating peptides targeting the Myconcoprotein for cancer treatment.
Investors
Founded Date:
2014-12-01
Technology:
Data-driven Technologies
Investor Type:
For Profit
Funding Status:
Early Stage Venture
Total Funding:
22792000.0
Employee Number:
1-10
Headquarters:
Barcelona, Catalonia, Spain
Last Funding Date:
2022-01-18
Investors Number:
10.0
Last Funding Type:
Venture - Series Unknown
Estimated Revenue:
Less than $1M
Industry:
Clinical Development